Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life

Table 2

Sickness impact profile, SIP (0% ∼Best).

(mean±SD, 𝑛=8)	1st year				2nd year
	Baseline	Week 13	Week 26	Week 52	Washout	Week 13	Week 26	Week 52	P-value
Treatment	None	GLP-2	GLP-2	GLP-2	None	GLP-2	GLP-2 + Cholyl-sarcosine	GLP-2	—
Overall	10.3±8.9	9.7±10.2	7.6±11.4§	6.2±9.5§§§	7.8±8.3	8.6±9.6	7.2±10.5§	6.7±8.4§§	—
Body care and movement	2.8±4.1	1.0±1.9	2.1±3.3	1.5±2.1	2.8±4.1	2.6±4.6	4.3±5.7	2.1±3.3	—
Mobility	13.8±18.5	13.8±20.7	7.5±17.5	7.5±13.9	7.5±10.4	11.3±18.9	12.5±25.5	8.8±18.1	—
Ambulation	5.3±7.8	6.3±9.8	1.0±2.8	2.1±6.0	5.3±7.8	4.3±7.9	3.1±6.3	4.1±8.9	—
Physical Dimension	5.9±7.8	5.4±7.6	3.0±6.1	3.0±5.5	4.3±5.1	5.0±7.6	5.8±9.6	4.3±7.3	—
Emotional behaviour	9.7±9.3	8.3±11.5	6.9±15.6	4.2±8.3	2.8±5.1	8.3±11.5	5.6±11.9	6.9±13.2	—
Social interaction	16.3±18.7	18.1±21.5	11.9±18.5	8.8±18.9	10.0±13.6	10.0±14.8	7.5±12.2§	9.4±10.2	—
Alertness behaviour	16.2±29.2	22.5±27.1	16.3±21.3	13.8±20.0	17.5±24.3	27.5±38.5	10.0±16.0	16.3±27.7	—
Communication	0.0±0.0	0.0±0.0	1.4±3.9	1.4±3.9	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	—
Psychosocial Dimension	11.9±11.6	13.9±15.8	9.8±15.1	7.5±13.7	8.3±11.0	11.5±11.1	6.1±9.5§§	8.6±11.2	—
Sleep and rest	21.4±20.2	14.3±13.2	23.2±32.3	16.1±19.4	23.2±24.1	10.7±14.8	21.4±35.0	12.5±16.1	—
Home management	11.3±13.6	11.3±16.4	6.3±14.1	6.3±10.6	8.8±11.3	7.5±11.9	8.8±17.3	5.0±10.7	—
Work	6.9±13.2	0.0±0.0	5.6±15.7	0.0±0.0	2.8±7.8	6.9±13.2	2.8±5.1	2.8±7.8	—
Recreation and pastimes	25.1±29.2	25.2±24.2	15.8±27.4	17.4±26.7	18.9±26.8	20.5±30.6	12.6±25.9	15.8±27.4	—
Eating	1.6±4.4	0.0±0.0	0.0±0.0	1.6±4.4	3.1±5.8	0.0±0.0	3.1±5.8	1.6±4.4	—
Independent Categories	12.8±10.2	10.4±8.7	9.3±12.9	8.4±9.9	10.8±10.5	8.3±8.6	9.8±14.4	7.3±8.9§	—
QOL VAS-score, 0–9 cm, 9 cm ∼best	4.1±2.8	5.1±2.8 *	5.8±2.6 *	5.9±2.4 *	4.7±3.3 *	5.8±2.8 *	5.6±2.5 *	6.0±2.4 *	0.01

QOL VAS-score ∼ Quality of life Visual Analog Scale, *∼𝑃<.05, compared to baseline by Dunnett’s test, §∼𝑃<.05, §§∼𝑃<.01,§§§∼𝑃<.001, compared to baseline by chi-square, alternatively Fisher exact test.